188 related articles for article (PubMed ID: 23912706)
1. Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells.
Chen RS; Ko JC; Chiu HC; Wo TY; Huang YJ; Tseng SC; Chen HJ; Huang YC; Jian YJ; Lee WT; Lin YW
Naunyn Schmiedebergs Arch Pharmacol; 2013 Dec; 386(12):1047-59. PubMed ID: 23912706
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide.
Tsai MS; Weng SH; Chen HJ; Chiu YF; Huang YC; Tseng SC; Kuo YH; Lin YW
Mol Cancer Ther; 2012 Mar; 11(3):561-71. PubMed ID: 22053010
[TBL] [Abstract][Full Text] [Related]
4. Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells.
Tung CL; Jian YJ; Chen JC; Wang TJ; Chen WC; Zheng HY; Chang PY; Liao KS; Lin YW
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):657-66. PubMed ID: 27026405
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.
Ko JC; Syu JJ; Chen JC; Wang TJ; Chang PY; Chen CY; Jian YT; Jian YJ; Lin YW
Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):383-91. PubMed ID: 26046675
[TBL] [Abstract][Full Text] [Related]
6. Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.
Tseng SC; Huang YC; Chen HJ; Chiu HC; Huang YJ; Wo TY; Weng SH; Lin YW
Biochem Pharmacol; 2013 Feb; 85(4):583-94. PubMed ID: 23228696
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells.
Ko JC; Chiu HC; Wo TY; Huang YJ; Tseng SC; Huang YC; Chen HJ; Syu JJ; Chen CY; Jian YT; Jian YJ; Lin YW
Lung Cancer; 2013 Dec; 82(3):397-406. PubMed ID: 24138903
[TBL] [Abstract][Full Text] [Related]
8. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Chiu YF; Kuo YH; Tsai MS; Lin YW
Lung Cancer; 2010 Aug; 69(2):155-64. PubMed ID: 19962780
[TBL] [Abstract][Full Text] [Related]
9. Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC.
Galan-Moya EM; de la Cruz-Morcillo MA; Llanos Valero M; Callejas-Valera JL; Melgar-Rojas P; Hernadez Losa J; Salcedo M; Fernández-Aramburo A; Ramon y Cajal S; Sánchez-Prieto R
PLoS One; 2011; 6(12):e28406. PubMed ID: 22164285
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
Del Bufalo D; Desideri M; De Luca T; Di Martile M; Gabellini C; Monica V; Busso S; Eramo A; De Maria R; Milella M; Trisciuoglio D
Mol Cancer; 2014 Oct; 13():230. PubMed ID: 25301686
[TBL] [Abstract][Full Text] [Related]
12. p38 Mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients.
Planchard D; Camara-Clayette V; Dorvault N; Soria JC; Fouret P
Cancer; 2012 Oct; 118(20):5015-25. PubMed ID: 22415779
[TBL] [Abstract][Full Text] [Related]
13. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
Jiang Y; Li C; Ma Y; Chen J; Li Y; Chen L
Clin Lab; 2012; 58(5-6):551-61. PubMed ID: 22783588
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of p38 MAPK Activation and Radiation-Sensitive 52 Expression Enhances 5-Fluorouracil and Erlotinib-Induced Cytotoxicity in Human Lung Squamous Cells.
Ko JC; Chen JC; Wei CL; Liu LL; Chien CC; Huang IH; Hsieh JM; Chiang CS; Tseng PY; Cheng HH; Tsao YC; Lin YW
Pharmacology; 2021; 106(11-12):623-636. PubMed ID: 34753130
[TBL] [Abstract][Full Text] [Related]
15. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Ceppi P; Rapa I; Lo Iacono M; Righi L; Giorcelli J; Pautasso M; Billè A; Ardissone F; Papotti M; Scagliotti GV
Int J Cancer; 2012 Apr; 130(8):1777-86. PubMed ID: 21618517
[TBL] [Abstract][Full Text] [Related]
16. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.
Liao KS; Wei CL; Chen JC; Zheng HY; Chen WC; Wu CH; Wang TJ; Peng YS; Chang PY; Lin YW
Regul Toxicol Pharmacol; 2016 Nov; 81():353-361. PubMed ID: 27693704
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
Tekle C; Giovannetti E; Sigmond J; Graff JR; Smid K; Peters GJ
Br J Cancer; 2008 Sep; 99(5):750-9. PubMed ID: 18728666
[TBL] [Abstract][Full Text] [Related]
18. DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance.
Wang S; Liu F; Zhu J; Chen P; Liu H; Liu Q; Han J
Med Sci Monit; 2016 Jun; 22():1999-2005. PubMed ID: 27289442
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.
Kawabata S; Chiang CT; Tsurutani J; Shiga H; Arwood ML; Komiya T; Gills JJ; Memmott RM; Dennis PA
Oncotarget; 2014 Feb; 5(4):1062-70. PubMed ID: 24658085
[TBL] [Abstract][Full Text] [Related]
20. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]